Literature DB >> 22088255

Cochlear implantation in a patient with superficial siderosis.

Hisashi Sugimoto1, Makoto Ito, Miyako Hatano, Tomokazu Yoshizaki.   

Abstract

Superficial siderosis is a rare disease characterized by accumulation of hemosiderin in the leptomeninges, subpial tissue, spinal cord, and cranial nerves. The first clinicopathological description was reported in 1908. Most patients (95%) experience progressive bilateral hearing loss that begins early in the course of disease. The initial management of a patient with hearing loss secondary to superficial siderosis involves sound amplification using hearing aids. However, cochlear implants can be considered in cases where the patient can no longer gain significant benefit from hearing aids. Only 10 studies have described the use of cochlear implants in superficial siderosis and results have been variable. We report the case of a 65-year-old woman with bilateral progressive sensorineural hearing loss caused by superficial siderosis who benefited significantly from cochlear implantation.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22088255     DOI: 10.1016/j.anl.2011.10.009

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  3 in total

1.  Outcomes of Cochlear Implantation in Patients with Superficial Siderosis: A Systematic Review and Narrative Synthesis.

Authors:  Abdullah Chaudhry; Daoud Chaudhry; Jameel Muzaffar; Gemma Crundwell; Peter Monksfield; Manohar Bance
Journal:  J Int Adv Otol       Date:  2020-12       Impact factor: 1.017

2.  Vestibular function in superficial siderosis.

Authors:  Toru Miwa; Ryosei Minoda; Hidetake Matsuyoshi
Journal:  BMC Ear Nose Throat Disord       Date:  2013-04-23

3.  Focused Neuro-Otological Review of Superficial Siderosis of the Central Nervous System.

Authors:  Aran Yoo; Jonathan Jou; Jeffrey D Klopfenstein; Jorge C Kattah
Journal:  Front Neurol       Date:  2018-05-28       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.